{"nctId":"NCT00201851","briefTitle":"Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer","startDateStruct":{"date":"2004-01"},"conditions":["Breast Cancer"],"count":740,"armGroups":[{"label":"Immediate surgery","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tamoxifen","Procedure: Surgery: Oophorectomy"]},{"label":"Scheduled surgery","type":"EXPERIMENTAL","interventionNames":["Drug: Tamoxifen","Procedure: Surgery: Oophorectomy"]},{"label":"Immediate Surgery - nonrandomized","type":"OTHER","interventionNames":["Drug: Tamoxifen","Procedure: Surgery: Oophorectomy"]}],"interventions":[{"name":"Tamoxifen","otherNames":["NolvadexÂ®"]},{"name":"Surgery: Oophorectomy","otherNames":["ovary removal surgery"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Open for accrual in Asia only\n* Female age 18-50,\n* premenopausal with regular cycles (\\>25-35 in length)\n* fine-needle aspiration diagnosis\n* Stage II-IIIA hormone receptor positive invasive breast cancer\n* No prior radiation or chemotherapy\n* Must be surgical candidate for bilateral oophorectomy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival","description":"5-year disease-free survival","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":244},"commonTop":[]}}}